$6.04
0.193.25%
Last update: Nov 3, 7:51 PM
Myriad Genetics Inc
MYGNNASDAQ
Myriad Genetics (MYGN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Myriad Genetics (MYGN) last issued guidance on September 16, 2026 for fiscal year 2026. The company guided revenue in the range of $770M - $790M for the period.
Compared to prior guidance, Myriad Genetics maintained its revenue forecast from a prior range of $770M - $790M.
Myriad Genetics has issued 28 guidance updates between February 28, 2023 and September 16, 2026. During this period, the company raised its outlook 7 times and lowered it 7 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.21 | $-0.06 | $-0.09 | $-0.05 |
| Actual | — | $-0.25 | $-0.09 | $0.04 |
| Surprise | — | -316.7% | 0.00% | +180.0% |
| Revenue | ||||
| Estimate | $190.8M | $205.9M | $202.5M | $207.6M |
| Actual | — | $190.7M | $200.4M | $209.8M |
| Surprise | — | -7.38% | -1.02% | +1.07% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-0.19 | $-0.23 | $-0.24 |
| Revenue | |||
| Consensus | $195.5M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $-0.25 | $-0.06 | -316.7 % |
| Q1 | May 5, 2026 | $-0.09 | $-0.09 | 0.00 % |
| Q4 | Feb 23, 2026 | $0.04 | $-0.05 | 180.0 % |
| Q3 | Nov 3, 2025 | $0 | $-0.05 | 100.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $190.70M | $205.89M | -7.38 % |
| Q1 | May 5, 2026 | $200.40M | $202.47M | -1.02 % |
| Q4 | Feb 23, 2026 | $209.80M | $207.57M | 1.07 % |
| Q3 | Nov 3, 2025 | $205.70M | $205.17M | 0.26 % |
